SAB Biotherapeutics, Inc.
SABS
$1.98
$0.1910.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.32M | 1.51M | 2.78M | 2.60M | 2.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.32M | 1.51M | 2.78M | 2.60M | 2.24M |
| Cost of Revenue | 30.45M | 27.10M | 23.29M | 20.13M | 16.51M |
| Gross Profit | -29.13M | -25.58M | -20.51M | -17.52M | -14.28M |
| SG&A Expenses | 13.78M | 26.19M | 25.28M | 24.54M | 23.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.23M | 53.29M | 48.57M | 44.67M | 40.31M |
| Operating Income | -42.91M | -51.78M | -45.79M | -42.06M | -38.08M |
| Income Before Tax | -34.11M | -45.57M | -40.32M | -39.87M | -42.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.11 | -45.57 | -40.32 | -39.87 | -42.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.11M | -45.57M | -40.32M | -39.87M | -42.19M |
| EBIT | -42.91M | -51.78M | -45.79M | -42.06M | -38.08M |
| EBITDA | -38.20M | -46.91M | -40.91M | -37.35M | -34.42M |
| EPS Basic | -3.68 | -5.84 | -5.69 | -6.26 | -7.18 |
| Normalized Basic EPS | -2.30 | -3.65 | -3.56 | -3.91 | -4.49 |
| EPS Diluted | -3.68 | -5.84 | -5.69 | -6.26 | -7.18 |
| Normalized Diluted EPS | -2.30 | -3.65 | -3.56 | -3.91 | -4.49 |
| Average Basic Shares Outstanding | 37.05M | 34.52M | 30.50M | 26.29M | 22.08M |
| Average Diluted Shares Outstanding | 37.05M | 34.52M | 30.50M | 26.29M | 22.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |